Higher-Order Structure Analysis
Coriolis Pharma offers industry-leading higher-order structure analysis services to ensure the quality, stability and efficacy of your biopharmaceutical products from the onset of R&D. Utilizing our scientific expertise and state-of-the-art technologies, we provide comprehensive structural characterization that supports your formulation development, stability studies and regulatory compliance requirements.
Orthogonal Analysis of the Higher-Order Structure
Coriolis offers an in-depth characterization of biopharmaceutical products’ higher-order structure throughout the development process.
Our expert scientists analyze various aspects of protein structure, including:
- Secondary structure
- Tertiary structure
- Quaternary structure (if applicable)
- Conformational stability
- Structural changes under stress conditions (pH, temperature, mechanical stress, freeze-thaw)
We provide orthogonal and sensitive data to comprehensively understand your product’s higher-order structure and behavior under various conditions.
Our higher-order structure services are performed under R&D and/or GMP conditions in dedicated labs with full quality oversight. In addition to protein drugs, these services can also be applied to viruses, cells and viral vectors that fall under biosafety level 2.
Higher-Order Structure Testing Methods
We can select the most suitable approach for your analytical challenge, whether following a standardized in-house workflow or a custom-tailored solution.
Analytical Method Development, Qualification and Validation
For common sample types, we can often apply standardized methods with little setup effort. However, when needed, our experienced analytical experts create or optimize custom methods tailored to your active pharmaceutical ingredient, product type and development phase.
Your Drug Product
Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges.
Your Phase
Our expert team has the expertise and experience to guide your biopharmaceutical development program from preclinical and early-phase development to the market.
Higher-Order Structure Resources
Publications
October 8, 2024
Publications
April 12, 2024
Publications
April 1, 2024